What is Massive Bio?
Founded in 2015 and headquartered in New York City, Massive Bio operates at the intersection of artificial intelligence and oncology. The company provides a comprehensive platform that connects cancer patients and oncologists to relevant clinical trials, effectively addressing the critical bottlenecks in patient identification and enrollment. By managing the entire value chain—from virtual pre-screening to resolving last-mile logistical challenges—Massive Bio enables faster drug development timelines for pharmaceutical companies, contract research organizations, and hospital networks.
The company's market position is further solidified by its recognition in the Digital Health 100 and its collaboration with the National Cancer Institute (NCI). Through its AI-driven ecosystem, Massive Bio not only improves patient access to innovative therapies but also generates actionable real-world insights that inform future protocol design, positioning itself as an essential partner in the global oncology research landscape.
How much funding has Massive Bio raised?
Massive Bio has raised a total of $11.7M across 3 funding rounds:
Other Financing Round
$2.6M
Debt
$74K
Other Financing Round
$9M
Other Financing Round (2020): $2.6M with participation from Revo Capital and Cavendish Impact Foundation
Debt (2021): $74K led by PPP
Other Financing Round (2022): $9M supported by Revo Capital
Key Investors in Massive Bio
Revo Capital
Revo Capital is a venture capital firm that invests in innovative, early-stage B2B and B2C technology ventures primarily in Turkey, Eastern Europe, and the Baltics, focusing on AI and fintech.
Cavendish Impact Foundation
An investment organization dedicated to supporting ventures that generate measurable social impact alongside financial returns.
PPP
Public-Private Partnership
What's next for Massive Bio?
With this latest strategic financing, Massive Bio is well-positioned to accelerate its mission of democratizing access to clinical trials. The company is expected to focus on scaling its AI-driven infrastructure to support a broader range of therapeutic areas and international markets. By deepening its integration with pharmaceutical enterprise customers, Massive Bio aims to further refine its patient recruitment algorithms and expand its data-as-a-service offerings.
Looking ahead, the firm will likely prioritize the commercialization of its DLCTMS, leveraging its NCI-backed research to set new industry standards for trial efficiency. As the oncology landscape becomes increasingly data-centric, Massive Bio's ability to provide high-fidelity, real-world evidence will be a key driver of its long-term competitive advantage and sustained growth in the digital health sector.
